Last year, the company was selected to conduct a government project for expanding production facilities for Covid-19 vaccines and raw materials, receiving 1.6 billion Korean won in support.

Hanmi FC said the Covid-19 pandemic has increased demand for high-level, synthetic biopharmaceutical raw materials, such as those used in mRNA vaccines, including lipid nanoparticles, nucleotides, capping materials, polyethylene glycol derivatives and peptides.

As well as conducting preclinical and clinical CDMO projects worth 10 billion won with 10 domestic and foreign companies, Hanmi FC expects to form partnerships with more companies in the second half of 2022.

The company noted that it has become globally competitive in the CDMO field by participating in R&D for parent company Hanmi Pharmaceutical’s biologics and anticancer drugs, as well as gaining GMP compliance in countries such as Germany, the UK, Japan and the US.

Hanmi FC is currently developing and manufacturing raw materials for its pharma parent’s investigational cancer drugs that include belvarafenib (in partnership with Genentech), MKI (in partnership with Aptose) and poziotinib (in collaboration with Spectrum.

Author: Elaine Burridge, Freelance Journalist